Why is Kailera Therapeutics, Inc. stock up today?
August 7, 2026
Kailera Therapeutics, Inc.
KLRA · NMS · USD
vs. prev. close $18.17
Last updated Aug 6, 2026 20:00
Intraday Chart — 5-min intervals
KLRA · less than a minute ago
Kailera Therapeutics, Inc. climbs 3.85% on fresh catalysts
Kailera Therapeutics, Inc. (KLRA) is rallying, at $18. 87 — up 3. 85% from yesterday's close of $18. 17. Today's move appears driven by recent headlines, including "2 Beaten-Down GLP-1 Stocks to Buy on the Dip" and "Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential". News sentiment around KLRA is leaning mixed.
The broader market is under pressure (S&P 500: -0. 2%, Nasdaq: -0. 1%, Dow Jones: -0. 9%, Shanghai: +1. 3%, Hang Seng: +0. 3%). Past performance does not guarantee future results.
Key Factors
Auto-generated analysis · Not financial advice
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Motley Fool·23 days agoneutralKailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
Insider Monkey·28 days agoneutralKailera weight loss pill trial results: Nausea sinks stock
Quartz·30 days agoneutralEli Lilly's Market Cap Balloons Again On This IPO's Setback
Investor's Business Daily·about 1 month agoneutralUpdate: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
MT Newswires·about 1 month agoneutralKailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
MT Newswires·about 1 month agoneutralKailera says obesity pill succeeds in late-stage trial in China
BioPharma Dive·about 1 month agoneutralKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
GlobeNewswire·about 1 month agoneutral
S&P 500
-0.18%
Nasdaq
-0.06%
Dow Jones
-0.85%
Shanghai
+1.35%
Hang Seng
+0.34%
Nikkei 225
-0.08%
FTSE 100
-0.19%
Nifty 50
-0.31%
DAX
+0.05%
OMX Stockholm
-0.12%
Search another stock